Basic proteomic study of monitoring method for anti-cancer drug resistance via receptor tyrosine kinases signaling reactivation

2016 Fiscal Year Final Research Report

• Project/Area Number: 26830099
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor diagnostics
• Research Institution: Yokohama City University
• Principal Investigator: KURATA Yoichi 横浜市立大学, 医学研究科, 特任助教 (70645564)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: プロテオミクス / 分子標的薬 / 抗ガン剤抵抗性 / ハウスキーピングタンパク質 / リン酸化 / 細胞外小胞

Outline of Final Research Achievements

Molecularly targeted therapy to receptor tyrosine kinase (RTK) suppresses the progression and metastasis of cancer and leads to improvement in QOL of patients with cancer and prolongation of survival. However long-term administration of RTK targeted drugs causes the emergence of drug-resistant cancer cells. Therefore, a biomarker, which can be to measure for the resistance or the response state against the RTK targeted drugs in the cancer cells, has great clinical significance. In this study, we found potential protein -biomarker candidates reflecting the activation state of RTK signaling in the RTK targeted drug -resistant GIST cell line by proteome analysis.

Free Research Field

プロテオミクス